News – Page 457 – Endpoints News

TCR upstart gets fresh funding as it looks to charge toward the clinic

3 years ago

Following program cuts and amid drug launch, Roivant lines up $1B shelf registration

3 years ago

Join me in Boston today to meet biotech's top startups

3 years ago

One SPAC's journey to find a partner, and its race against the clock, shows toughness of bear market

3 years ago

Renovacor ships its cardiac gene therapy to Rocket in $53M all-stock deal

3 years ago

Months after launching with lofty goal, Flagship startup streamlines ops, chops headcount

3 years ago

#ESMO22: Roundtable discussion with John Carroll

3 years ago

Heron secures FDA approval after R&D head count chop

3 years ago

Phlow looks to raise $50M as US aims to boost domestic manufacturing

3 years ago

Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall

3 years ago

Astellas taps TikTok influencers to talk menopause symptoms in a first pharma move

3 years ago

Vanda inks $11.5M deal to settle off-label drug promotion accusations

3 years ago

Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns

3 years ago

Blaming Covid-19 for initial data issues, antiviral biotech reports PhIIb fibromyalgia fail — shares tank

3 years ago

As Gamida Cell eyes its first cell therapy approval, Julian Adams is heading out

3 years ago

Ventyx seeks to rack up $176M+ in its latest move as the market become bullish on TYK2

3 years ago

With hit-and-miss data, Allakos goes the public offering route in $150M ask

3 years ago

Rejection No. 2 for Medexus' decades-old chemo drug; Trevi touts chronic cough data

3 years ago

First the US, now the EU: Pfizer’s 20-valent pneumococcal jab for infants headed to regulators

3 years ago

Theravance declares independence from GSK, crafts $250M plan to buy back its own shares

3 years ago

Bluebird lands another rare disease gene therapy OK — but there are a few caveats to note

3 years ago

Still carrying the budget axe, Kåre Schultz is wrapping up his stint at Teva, promising to start paying opioid ...

3 years ago

After selling failed NASH drug to Ipsen, French startup nabs a liver disease player in small buyout

3 years ago

On heels of Lumakras data drop, new KRAS idea emerges; Bristol Myers, AbbVie, Rubius headline busy week of ...

3 years ago

First page Previous page 454 455 456457458 459 460 Next page Last page